started · updated
Novartis to license mRNA therapies from Abogen in $7.8 billion deal
Swiss pharmaceutical giant Novartis has entered into a licensing and options agreement with Chinese biotechnology group Abogen Biosciences. The transaction is valued at up to $7.8 billion, consisting of a $575 million upfront payment and up to $7.2 billion in milestone-based conditional payments.
Under the terms of the deal, Novartis secures worldwide exclusive rights to Abogen’s lead therapeutic candidate, ABO2203, as well as exclusive options for future programs developed on Abogen’s proprietary mRNA platform. ABO2203 is an mRNA-encoded T-cell engager designed to treat B-cell mediated autoimmune diseases.
Unlike traditional therapies, this technology uses messenger RNA to instruct the body to produce molecules in vivo that eliminate dysfunctional B cells. This approach aims to provide a differentiated mechanism and superior scalability compared to traditional recombinant therapies.
Entities
Abogen Biosciences · European Union · Luca Niculescu · Marian Neacșu · Ministry of Internal Affairs · Novartis · Romania